Sign up
Pharma Capital

AquaBounty on the verge of a major growth spurt as they transition from R&D to operations

Ronald Stotish, president and chief executive of AquaBounty Technologies (NASDAQ:AQB), tells Proactive they're a small biotechnology company that was founded roughly 20 years ago with the strategic intent to apply the tools of modern molecular biology and molecular genetics to aquaculture.

''We believe that aquaculture is one of the ways to meet future quality protein needs in a sustainable and environmentally-friendly way and we believe there are tremendous opportunities by applying modern molecular biology and molecular genetics to improve productivity and the efficiency of production of seafood''.

''We know we have a good product, our experience to date has been  good and at the moment we've achieved something that no-one else has done''.

''We're pioneers in this area and we believe that we're about to enter into a business that will help meet global food security needs for the next 50 years''.


View full AQB profile View Profile

AquaBounty hails Canada court ruling

View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.